Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.76 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.76 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31126374 | 1.00 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL18292495 | 0.91 | TLR7 (0.71) | TLR7TLR8NUDT1 | |
| SCHEMBL24809666 | 0.91 | TLR7 (0.80) | TLR7TLR8NUDT1 | |
| SCHEMBL29639773 | 0.91 | TLR7 (0.80) | TLR7TLR8NUDT1 | |
| SCHEMBL5471062 | 0.90 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL8570489 | 0.90 | TLR7 (0.79) | TLR7TLR8NUDT1 | |
| SCHEMBL2744084 | 0.90 | TLR7 (0.62) | TLR7TLR8NUDT1 | |
| SCHEMBL1490576 | 0.89 | TLR7 (0.74) | TLR7TLR8NUDT1 | |
| SCHEMBL29639780 | 0.89 | TLR7 (0.84) | TLR7TLR8NUDT1 | |
| SCHEMBL24808211 | 0.89 | TLR7 (0.84) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-26 | — | — | US | claimed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | claimed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | claimed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | claimed |
| US-12214045-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | NEKTAR THERAPEUTICS (US) | 2025-02-04 | — | — | US | disclosed |
| US-12054553-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-08-06 | — | — | US | disclosed |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2023-11-23 | — | — | US | disclosed |
| US-20210292425-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | NEKTAR THERAPEUTICS | 2021-09-23 | — | — | US | disclosed |
| WO-2021093779-A1 | IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | NEKTAR THERAPEUTICS | 2021-05-06 | — | — | US | disclosed |
| EP-3668548-A2 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | Nektar Therapeutics (US) | 2020-06-24 | — | — | EP | disclosed |
| US-6348462-B1 | VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-02-19 | — | — | US | disclosed |
| US-5977366-A | 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0872478-A2 | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5741909-A | PHARMACEUTICAL COMPOSITIONS WHICH ACT AS ANTIVIRAL AGENTS, INDUCE BIOSYNTHESIS OF INTERFERON AND INHIBIT TUMOR FORMATION IN ANIMALS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | CD274, TLR7, PDCD1LG2 | TLR7 2/4885TLR8 5/4885NUDT1 2779/4885 |
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885NUDT1 1567/4885 |
| US-12214045-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885NUDT1 2266/4885 |
| US-12054553-B2 | Immunotherapeutic tumor treatment method | IL2RA, IL2, TLR3 | TLR7 6/4885TLR8 15/4885NUDT1 3163/4885 |
| US-20210292425-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | IL2RA, IL2, TLR3 | TLR7 6/4885TLR8 15/4885NUDT1 3163/4885 |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | IRF3, IFNAR1, IFNG | TLR7 105/4885TLR8 336/4885NUDT1 61/4885 |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | CD274, TLR7, PDCD1LG2 | TLR7 2/4885TLR8 5/4885NUDT1 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.